Market Cap 593.59M
Revenue (ttm) 262.60M
Net Income (ttm) -80.80M
EPS (ttm) N/A
PE Ratio 89.70
Forward PE N/A
Profit Margin -30.77%
Debt to Equity Ratio 0.00
Volume 554,700
Avg Vol 815,440
Day's Range N/A - N/A
Shares Out 64.52M
Stochastic %K 93%
Beta 1.71
Analysts Sell
Price Target $14.00

Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein fo...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 535 1456
Address:
5 Science Park, 395 Winchester Avenue, New Haven, United States
Estimize
Estimize Aug. 12 at 10:01 AM
Wall St is expecting -0.78 EPS for $ARVN Q3 [Reporting 11/10 BMO] http://www.estimize.com/intro/arvn?chart=historical&metric_name=eps&utm_c
0 · Reply
BullDonald
BullDonald Aug. 10 at 3:43 PM
$ARVN one Positive DATA on Oncology and $15 to $20 strong Institution support after Earning. +
0 · Reply
BullDonald
BullDonald Aug. 7 at 10:49 AM
0 · Reply
EquityVoyager_1
EquityVoyager_1 Aug. 6 at 10:31 PM
Today’s Relative Volume Leaders -Smart Money Is Making Noise High-volume names that stood out on today’s scan: $PEPG - Relative Volume: 7.6x $CHYM - Relative Volume: 6.0x $HTZ - Relative Volume: 6.0x $ARVN - Relative Volume: 2.7x $SATL -Relative Volume: 2.3x Volume often reveals where attention is flowing before price follows. These names made the list because the trading activity was simply too strong to ignore. Another alert is coming soon. If notifications are off, chances are you’ll only notice the move once it’s already in progress.
1 · Reply
biopuzzle
biopuzzle Aug. 5 at 5:41 PM
$ARVN Noah is probably selling again... so tired of it.
0 · Reply
Shelz912
Shelz912 Aug. 5 at 2:40 PM
$ARVN Q2 pretty good. Why Q3 Estimates so bad?
0 · Reply
anachartanalyst
anachartanalyst Aug. 5 at 2:02 PM
$ARVN https://anachart.com/wp-content/uploads/2026/08/1785938519_soc-img.jpg
0 · Reply
BullDonald
BullDonald Aug. 5 at 1:50 PM
$ARVN BTIG Reiterates Buy on Arvinas, Maintains $18 Price Target
0 · Reply
BullDonald
BullDonald Aug. 5 at 1:37 PM
$ARVN man, its a long Haul. only 65M shares out standing with storng Management with no Liquidation risk.
0 · Reply
biopuzzle
biopuzzle Aug. 4 at 2:35 PM
$ARVN @outlawinvestor1 GM, hope you are doing well. I missed part of CC today. Did they explain why Noah left? Thank you
1 · Reply
Latest News on ARVN
Arvinas price target lowered to $14 from $19 at Evercore ISI

2026-08-10T12:15:27.000Z - 9 days ago

Arvinas price target lowered to $14 from $19 at Evercore ISI


Arvinas price target lowered to $21 from $24 at Citi

2026-08-10T10:50:18.000Z - 9 days ago

Arvinas price target lowered to $21 from $24 at Citi


Arvinas price target raised to $12 from $11 at Wedbush

2026-08-05T14:29:36.000Z - 13 days ago

Arvinas price target raised to $12 from $11 at Wedbush


Arvinas reports Q2 EPS $2.58, consensus (28c)

2026-08-04T12:06:34.000Z - 15 days ago

Arvinas reports Q2 EPS $2.58, consensus (28c)


Arvinas Earnings Call Transcript: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 15 days ago

Arvinas Earnings Call Transcript: Q2 2026


Arvinas Earnings release: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 15 days ago

Arvinas Earnings release: Q2 2026


Arvinas Quarterly report: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 15 days ago

Arvinas Quarterly report: Q2 2026


Arvinas Transcript: AGM 2026

Jun 24, 2026, 8:00 AM EDT - 2 months ago

Arvinas Transcript: AGM 2026


Arvinas Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 9:55 AM EDT - 2 months ago

Arvinas Transcript: Jefferies Global Healthcare Conference 2026


Arvinas to Present at Jefferies Global Healthcare Conference

May 29, 2026, 4:01 PM EDT - 2 months ago

Arvinas to Present at Jefferies Global Healthcare Conference


Arvinas Employees Give Back During Company-wide Impact Day

May 18, 2026, 10:30 AM EDT - 3 months ago

Arvinas Employees Give Back During Company-wide Impact Day


Arvinas price target raised to $16 from $14 at BofA

2026-05-13T19:22:15.000Z - 3 months ago

Arvinas price target raised to $16 from $14 at BofA

PFE RIGL


Arvinas price target raised to $18 from $16 at BTIG

2026-05-13T12:47:37.000Z - 3 months ago

Arvinas price target raised to $18 from $16 at BTIG

RIGL


Arvinas price target raised to $20 from $18 at Barclays

2026-05-13T09:00:59.000Z - 3 months ago

Arvinas price target raised to $20 from $18 at Barclays


Arvinas Earnings Call Transcript: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Arvinas Earnings Call Transcript: Q1 2026


Arvinas Quarterly report: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Arvinas Quarterly report: Q1 2026


Arvinas Earnings release: Q1 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Arvinas Earnings release: Q1 2026


Arvinas reports Q1 EPS (90c), consensus (63c)

2026-05-12T11:49:11.000Z - 3 months ago

Arvinas reports Q1 EPS (90c), consensus (63c)


Arvinas management to meet with BTIG

2026-05-04T19:30:43.000Z - 3 months ago

Arvinas management to meet with BTIG


Arvinas price target raised to $24 from $21 at Citi

2026-05-04T09:10:10.000Z - 3 months ago

Arvinas price target raised to $24 from $21 at Citi


Arvinas gets early approval for Vepdeg, says Truist

2026-05-01T17:15:17.000Z - 3 months ago

Arvinas gets early approval for Vepdeg, says Truist


US FDA approves Pfizer, Arvinas' breast cancer drug

May 1, 2026, 12:37 PM EDT - 3 months ago

US FDA approves Pfizer, Arvinas' breast cancer drug

PFE


Arvinas Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Arvinas Proxy statement: Proxy filing


Arvinas Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Arvinas Proxy statement: Proxy filing


Arvinas Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 4:20 PM EDT - 5 months ago

Arvinas Transcript: Leerink Global Healthcare Conference 2026


Arvinas Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 1:10 PM EST - 6 months ago

Arvinas Transcript: TD Cowen 46th Annual Health Care Conference


Arvinas Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:00 AM EST - 6 months ago

Arvinas Earnings Call Transcript: Q4 2025


Arvinas Annual report: Q4 2025

Feb 24, 2026, 8:00 AM EST - 6 months ago

Arvinas Annual report: Q4 2025


Arvinas Earnings release: Q4 2025

Feb 24, 2026, 8:00 AM EST - 6 months ago

Arvinas Earnings release: Q4 2025


Arvinas to Participate in Upcoming Investor Conferences

Feb 23, 2026, 7:00 AM EST - 6 months ago

Arvinas to Participate in Upcoming Investor Conferences


Arvinas Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 3:30 AM EST - 9 months ago

Arvinas Transcript: Jefferies London Healthcare Conference 2025


Arvinas Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

Arvinas Earnings Call Transcript: Q3 2025


Arvinas Quarterly report: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

Arvinas Quarterly report: Q3 2025


Arvinas Earnings release: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

Arvinas Earnings release: Q3 2025


Arvinas Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Arvinas Earnings Call Transcript: Q2 2025


Arvinas Quarterly report: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Arvinas Quarterly report: Q2 2025


Arvinas Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Arvinas Earnings release: Q2 2025


Arvinas Transcript: Study Update

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Arvinas Transcript: Study Update


Arvinas Press release: Study Update

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Arvinas Press release: Study Update


Arvinas Slides: Study Update

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Arvinas Slides: Study Update


Estimize
Estimize Aug. 12 at 10:01 AM
Wall St is expecting -0.78 EPS for $ARVN Q3 [Reporting 11/10 BMO] http://www.estimize.com/intro/arvn?chart=historical&metric_name=eps&utm_c
0 · Reply
BullDonald
BullDonald Aug. 10 at 3:43 PM
$ARVN one Positive DATA on Oncology and $15 to $20 strong Institution support after Earning. +
0 · Reply
BullDonald
BullDonald Aug. 7 at 10:49 AM
0 · Reply
EquityVoyager_1
EquityVoyager_1 Aug. 6 at 10:31 PM
Today’s Relative Volume Leaders -Smart Money Is Making Noise High-volume names that stood out on today’s scan: $PEPG - Relative Volume: 7.6x $CHYM - Relative Volume: 6.0x $HTZ - Relative Volume: 6.0x $ARVN - Relative Volume: 2.7x $SATL -Relative Volume: 2.3x Volume often reveals where attention is flowing before price follows. These names made the list because the trading activity was simply too strong to ignore. Another alert is coming soon. If notifications are off, chances are you’ll only notice the move once it’s already in progress.
1 · Reply
biopuzzle
biopuzzle Aug. 5 at 5:41 PM
$ARVN Noah is probably selling again... so tired of it.
0 · Reply
Shelz912
Shelz912 Aug. 5 at 2:40 PM
$ARVN Q2 pretty good. Why Q3 Estimates so bad?
0 · Reply
anachartanalyst
anachartanalyst Aug. 5 at 2:02 PM
$ARVN https://anachart.com/wp-content/uploads/2026/08/1785938519_soc-img.jpg
0 · Reply
BullDonald
BullDonald Aug. 5 at 1:50 PM
$ARVN BTIG Reiterates Buy on Arvinas, Maintains $18 Price Target
0 · Reply
BullDonald
BullDonald Aug. 5 at 1:37 PM
$ARVN man, its a long Haul. only 65M shares out standing with storng Management with no Liquidation risk.
0 · Reply
biopuzzle
biopuzzle Aug. 4 at 2:35 PM
$ARVN @outlawinvestor1 GM, hope you are doing well. I missed part of CC today. Did they explain why Noah left? Thank you
1 · Reply
BullDonald
BullDonald Aug. 4 at 1:42 PM
$ARVN Biggest Positives 1. ARV-393 enrollment is finally accelerating 2. They're already talking about pivotal opportunities 3. SBMA program is progressing exactly as planned 4. Cash runway 5. Capital allocation Some hickups but Not Negative ARV-102 delayed due to regulatory process but Positive as they are in discusion with FDA, Europe and in Japan BCL6 data expectations is lowered intentionally by the management because of lower doses. Higly WELL MANAGED company VIBE that Big investors LOVE.
0 · Reply
EarningsInsider
EarningsInsider Aug. 4 at 1:17 PM
https://www.marketbeat.com/earnings/reports/2026-8-4-arvinas-inc-stock/ $ARVN Arvinas Earnings Transcript
0 · Reply
lex007
lex007 Aug. 4 at 12:41 PM
$ARVN interesting news and long term gem
0 · Reply
NewGuyHere94
NewGuyHere94 Aug. 4 at 11:39 AM
0 · Reply
Biotech80
Biotech80 Aug. 4 at 11:15 AM
$ARVN 💎💎💎💎💎💎
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 4 at 11:08 AM
$ARVN Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $2.61 up 410.71% YoY • Reported revenue of $249.7M up 1014.73% YoY • Arvinas believes its cash, cash equivalents, and marketable securities of $567.9 million as of June 30, 2026, is sufficient to fund planned operating expenses and capital expenditure requirements into 2028.
0 · Reply
NewGuyHere94
NewGuyHere94 Jul. 31 at 12:38 PM
$ARVN earnings next week, hopefully some data release. Still very optimistic
0 · Reply
diegosan21
diegosan21 Jul. 30 at 1:00 PM
$ARVN what's the news here?
1 · Reply
BullDonald
BullDonald Jul. 22 at 4:20 PM
$ARVN she is waking up.... 2 digits soon. Possible. release the Data
0 · Reply
Jtlo
Jtlo Jul. 17 at 12:10 PM
$ARVN premarket is very strange here
0 · Reply
NewGuyHere94
NewGuyHere94 Jul. 15 at 11:42 AM
$ARVN think we’ll essentially be sitting in the $8’s until the next set of trial results come to light, been in this for awhile but still think much to grow on here!
1 · Reply
BullDonald
BullDonald Jul. 14 at 11:54 PM
0 · Reply